PHARMACOKINETIC (PK) / PHARMACODYNAMIC (PD) MODEL OF FTY 720 IN HUMANS

Mark T. Marino(Hochschule Hannover), Robert Schmouder(Novartis (United States)), R. Brunkhorst(Klinikum Region Hannover), L Brookman(Novartis (Switzerland)), P Lücker(Hochschule Hannover), Neumayer Hh(Hochschule Hannover), S Choudhury(Hochschule Hannover)

Transplantation

April 1, 1999

10.1097/00007890-199904150-00817

Cited by 0

Related Papers

Epidemiology of sepsis in Germany: results from a national prospective multicenter study

|Intensive Care Medicine|2007|623

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

|BMJ|2012|309

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

|Journal of the American Society of Nephrology|2002|274

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study

|Arthritis & Rheumatism|1998|261

A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

|Arthritis & Rheumatism|2006|255